BioClin Therapeutics' Series B Round

BioClin Therapeutics raised a round of funding on March 21, 2017.

BioClin Therapeutics is a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet…

Articles about BioClin Therapeutics' Series B Round: